Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets

The human insulin market is segmented based on types of insulin, and branded drugs available in the market (http://www.marketsandmarkets.com/Market-Reports/human-insulin-market-229295783.html).

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
MarketsandMarkets

MarketsandMarkets

Novo Nordisk (Denmark), Eli Lilly (U.S), Sanofi Aventis(France),Biocon (India), Julphar(U.A.E),Wockhardt (India),SemBioSys (Canada), and GSK (U.K.).

(PRWEB) August 20, 2014

The “Human Insulin Market by Product Type [Human Insulin (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid Acting, Long Acting, Premixed)], by Brand (Lantus, Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast to 2019” provides a detailed overview of the major drivers,restraints, challenges, opportunities, current market trends,and strategies impacting the global human insulin market along with the estimates and forecasts of the revenue and share analysis.

Browse 110 market data tables and 55 figures spread through 232 pages and in-depth TOC - http://www.marketsandmarkets.com/Market-Reports/human-insulin-market-229295783.html.

Early buyers will receive 10% customization on this report.

The global human insulin market crossed $23 billion in 2013 and is poised to grow at a high double-digit CAGR from 2014 to 2019.

Download PDF Brochure @ http://www.marketsandmarkets.com/pdfdownload.asp?id=229295783

The market is segmented based on products, and types of insulin. Based on products, the global human insulin market is segmented into biologics and biobetters, and biosimilars/biogenerics. Human insulin market is also segmented into traditional and modern human insulin. Of these, modern human insulin and biosimilarswill be the fastest-growing market in the next five years.The major factors propelling this growth are cost effective treatment offered while using modern human insulin and low price of biosimilars/biogeneric drugs of human insulin thereby stimulating the demand for biosimilar human insulin products.

Request for Customization of Report @ http://www.marketsandmarkets.com/requestCustomization.asp?id=229295783

By type of insulin, traditional human insulin is further segmented into short acting human insulin, intermediate acting human insulin, and premixed whereas Modern human insulin is fragmented into long acting human insulin, rapid acting human insulin, and premixed modern human insulin. Of all, long acting human insulin accounted for the largest share and pre-mixed human insulin will be the fastest growing market witnessing double-digit growth between 2014-2019. Lantus was the best-selling drug in the year 2013 whereas Apidra and Levemirare estimated to be the two fastest growing drugs in the human insulin market.

Geographic analysis reveals that North America is the largest contributor to the global human insulin market in 2014 and will witness moderate growth between 2014-2019. Factors driving the North American market are the growing healthcare cost that enforce more consumption of modern human insulin due to its significant cost effectiveness, spiraling aging population, expanded diabetic population, and biologics such as Lantus, Novorapid, and Novomixgoing off-patent that opens the door for biosimilar, biogenerics, and biobetters of these branded products.

Asia-Pacific will be the fastest growing market for human insulin production, development, and distribution. Further, Asia-Pacific countries are considered to be the lucrative ones for investors to invest in for manufacturing and clinical activities of pipeline and existing human insulin product. Major players enter the Asian market with the purpose to collaborate with various CMO and CRO existing in this region that fosters the development of human insulin at lower cost compared to the other region across the globe. The demand for human insulin will be on the rise in coming five years due to the high prevalence rate of diabetes as well as low price of human insulin.

The key players in the market are Novo Nordisk (Denmark), Eli Lilly (U.S), Sanofi Aventis(France),Biocon (India), Julphar(U.A.E),Wockhardt (India),SemBioSys (Canada), and GSK (U.K.).

Browse Related Reports:
Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018
http://www.marketsandmarkets.com/Market-Reports/whole-exome-sequencing-market-107180258.html

Healthcare Workforce Management Systems Market by Solution (Talent Management, Time & Attendance, Scheduling, Optimization Services), by Mode of Delivery (Cloud-based, Web-based), by End-User (Hospital, Long Term Care) - Global Forecast to 2019
http://www.marketsandmarkets.com/Market-Reports/healthcare-workforce-management-systems-market-92262366.html

About MarketsandMarkets
MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotive and transportation, banking and financial services, biotechnology, chemicals, consumer goods, telecommunications and IT, energy and power, food and beverages, industrial automation, healthcare IT, medical devices, pharmaceuticals, semiconductor and electronics, aerospace & defense.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Contact:
Mr. Rohan
North - Dominion Plaza
17304 Preston Road
Suite 800, Dallas, TX 75252
Tel: +1-888-600-6441
Email: sales(at)marketsandmarkets(dot)com
Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/pharmaceuticals
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets


Contact